30 closest matches · ranked by relevance
Congenital Adrenal Hyperplasia (CAH)
Primary: Adult Height Relative to General Population — -0.34; -0.6 Standard Deviation Score (SDS) units
Adrenal Insufficiency · Excess Androgen · Congenital Adrenal Hyperplasia (CAH)
Primary: Number of Patients With 17-OHP Levels Equal or Below 1,200 ng/dL at 0700 — 0 Participants
Congenital Adrenal Hyperplasia · 21-Hydroxylase Deficiency · Adrenogenital Syndrome
Primary: Chronocort vs. Cortef Cortisol Concentrations (AUC Over 24 Hours - Time Points 0,.5,1,1.5,2,3,4,5,6,7,8,10,10.5,11, 11.5,12,13,15,17,17.5,18,18.5,19,20,22,24 Post Dose)…
Congenital Adrenal Hyperplasia
Primary: Number of Participants With Reduction of 17-hydroxyprogesterone to </= 2 Times the Upper Limit of Normal at Any Time Following 2 Weeks of Dosing With ATR-101 — 2…
CAH - Congenital Adrenal Hyperplasia
Primary: Percent Change From Baseline to Day 14 in 17-hydroxyprogesterone (17-OHP) Morning Window Averages — -60; -58; -53; -64 Percent (%)
Congenital Adrenal Hyperplasia
Primary: Change From Baseline to 24 Weeks of the Mean of the 24-hour Standard Deviation Score (SDS) Profile for 17-OHP — -0.403; -0.172 Z-score — p==0.5521
Congenital Adrenal Hyperplasia · Hyperplasia · Adrenal Hyperplasia
Primary: Cortisol Exposure — 110 hr*mcg/dL
Adrenal Insufficiency
Primary: Serum Cortisol Concentration up to 240 Minutes — 575.8 nmol/L
Adrenal Hyperplasia, Congenital
Primary: Percent Difference in the Mean Log Transformed Area Under the Curve of 17-hydroxyprogesterone Between Regimens — 3.16; 3.91 Log Mean Area Under the Curve — p=0.09
Congenital Adrenal Hyperplasia · CAH - Congenital Adrenal Hyperplasia
Primary: Safety of SPR001 in Patients With CAH — 6; 5; 4 Participants
Congenital Adrenal Hyperplasia
Primary: Percentage of Participants Who Were Biochemical Responders at Week 28 — 40.0; 14.3 percentage of participants — p=0.0003
Congenital Adrenal Hyperplasia · CAH - Congenital Adrenal Hyperplasia · CAH - 21-Hydroxylase Deficiency
Primary: The Incidence of Treatment-emergent Adverse Events (Safety and Tolerability) in Subjects With CAH — 9; 2 Participants
CAH - Congenital Adrenal Hyperplasia
Primary: Percent Change From Baseline to Day 14 in Serum 17-OHP Concentrations (Morning Window Average) — -69.48 percent change
Development
Primary: 17-hydroxyprogesterone Response to ACTH — 2.4; 3.7; 3.1; 2.9 ng/mL
Endocrine Disease · Adrenal Insufficiency · Congenital Adrenal Hyperplasia
Primary: Pharmacokinetic Profile (Cmax) Following Short-term Treatment With Chronocort® in Adult Patients With Congenital Adrenal Hyperplasia — 601.213 nmol/L
Polycystic Ovary Syndrome
Primary: Estradiol Level in Female Offspring — 18606; 6467 pg/ml — p=0.049
PCOS
Primary: 17OHP Levels After hCG — 3.2; 1.3 ng/ml
Nephrotic Syndrome
Primary: Number of Participants Experienced a Relapse of Nephrotic Syndrome — 14; 15 Participants
Mild Hypercortisolism
Primary: A1C Level — 6.2; 6.1375; 6.125 percentage of red blood cells
Polycystic Ovary Syndrome
Primary: 17-hydroxyprogesterone Responses to hCG in PCOS Women and Normal Controls — 1.3; 3; 1.1 ng/ml
Congenital Adrenal Hyperplasia
Primary: Safety and Tolerability - Number of Participants With Adrenal Insufficiency — 25; 41 Participants
Congenital Hyperinsulinism
Primary: Median of Average Daily Percent Time Within a Glucose Target Range of 70-180 mg/dL (3.9-10 mmol/L) by CGM at Baseline (BL) and End of Treatment (EOT) — 81.7; 72.9; 83.4…
Acne Vulgaris
Primary: Change in HPA Axis Response as Measured by CST — 12.50; 22.95 mcg/dL
Stage I Adrenal Cortical Carcinoma AJCC v7 · Stage II Adrenal Cortical Carcinoma AJCC v7 · Stage III Adrenal Cortical Carcinoma AJCC v7
Primary: Five Year Event-free Survival (EFS) — 0.86; 0.53; 0.51 Estimated probability five year EFS — p=0.44
Adrenal Insufficiency
Primary: Incidence of Serious Adverse Events (SAEs) and Adverse Events (AEs) — 193; 9; 0; 42 adverse events
Congenital Hyperinsulinism
Primary: Number of Subjects With Clinically Meaningful Reduction in Glucose Infusion Rate (Double-Blind) — 2; 0 Participants
Adrenal Insufficiency · Cirrhosis · Spur Cell Anemia
Primary: Number of Participants With Cholesterol Esterification Deficiency — 10; 11 Participants
Congenital Hyperinsulinism · Hyperinsulinism · Persistent Hyperinsulinemic Hypoglycemia of Infancy
Primary: The Accuracy of FDOPA PET to Identify Focal Forms of Hyperinsulinism — 40; 6; 3; 46 Participants
Hypercortisolism
Primary: Change in Average 24-hour SBP — -5.56; -2.89 mm Hg — p=0.4160
Pseudohypoparathyroidism · Albright Hereditary Osteodystrophy
Primary: Intelligence Quotient — 85.9; 104.3; 103.2 units on a scale